GPR35; ADRA1A; ADRA2C; ADRA2A; ADRA2B; ADRB3; DRD4; DRD1; DRD2; | |
OPRD1; TSHR; NPSR1; CXCR1; NMUR2; | |
PDE4D; | |
ALPL; RECQL; TDP1; PLA2G1B; BLM; CTDSP1; P4HB; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; GFER; AKR1B10; NOX4; USP2; PYGL; APEX1; POLB; AOX1; | |
MGAM; ACHE; GAA; | |
PTPN1; DUSP3; | |
TRPA1; | |
NEK6; AKT1; MET; CAMK2B; GSK3B; CSNK2A1; DAPK1; NEK2; FLT3; ABL1; SRC; IGF1R; PTK2; BRAF; AURKB; AURKA; FLT4; EPHB4; MAP3K8; TEK; PDGFRB; INSR; PLK4; CDK1; MAPK1; EGFR; ERBB2; PIM1; NUAK1; ALK; AXL; KDR; PLK1; PKN1; | |
CA7; CA3; CA14; CA5B; CA5A; CA1; CA12; CA9; CA13; CA4; CA6; CA2; | |
AR; | |
THRB; | |
ESRRB; ESRRA; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; ALDH2; ALOX5; TYR; XDH; | |
CASP7; CASP1; | |
MMP13; MMP3; MMP2; MMP9; MMP1; | |
BACE1; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
FUT7; | |
ABCC1; ABCB1; ABCG2; | |
SLC22A6; SLCO1B1; SLCO1B3; | |
SMAD3; LMNA; MAPT; HBB; THPO; RAB9A; NPC1; XPO1; HSPA1A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Phosphodiesterase 4 | PDE4D | Phosphodiesterase 4D | Q08499 | CHEMBL288 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | XPO1 | Exportin-1 | O14980 | CHEMBL5661 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0020037; heme binding | 7.254E-13 | 1.264E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, MPO, NOX4, SRC, TBXAS1 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.168E-11 | 4.106E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.543E-11 | 7.017E-09 | AR, BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP1, MMP13, MMP2, MMP3, MMP9, PTPN1, SMAD3, THRB, TP53 |
BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 7.899E-11 | 9.828E-09 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD2, PDE4D |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.281E-10 | 1.541E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.452E-10 | 2.840E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
MF | Unclassified; | GO:0004872; receptor activity | 5.774E-10 | 6.256E-08 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, AHR, ALK, AR, AXL, CXCR1, DRD1, DRD2, DRD4, EGFR, EPHB4, ERBB2, ESR1, ESR2, ESRRA, ESRRB, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, OPRD1, PDGFRB, TEK, THRB, TSHR |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.181E-09 | 1.225E-07 | ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD4 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.408E-09 | 1.440E-07 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, SLCO1B1, SLCO1B3, TEK, TSHR |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.546E-09 | 1.573E-07 | AXL, EGFR, ERBB2, INSR, MET, NOX4, PDGFRB, PIK3R1, PTK2, SRC, TEK, THPO |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.841E-09 | 2.737E-07 | ABL1, ADRA1A, ALOX15, BRAF, DRD2, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK, THPO |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.963E-09 | 2.829E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.651E-09 | 6.941E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.486E-08 | 1.269E-06 | ABL1, AURKB, CA2, CA7, DRD1, DRD2, EGFR, HIF1A, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.631E-08 | 1.382E-06 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.631E-08 | 1.382E-06 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.654E-08 | 1.396E-06 | ABL1, ADRA2A, AURKB, CA2, CA7, DRD1, DRD2, EGFR, HIF1A, KDR, MAPK1, NEK2, NPC1, NPSR1, PDE4D, PLA2G1B, SRC, TRPA1 |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.928E-08 | 1.608E-06 | ADRA1A, ADRB3, AKT1, APEX1, AURKB, CDK1, CYP1A1, MPO, NOX4, PDE4D, PDGFRB, POLB, TP53 |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 4.053E-08 | 3.233E-06 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, ALK, AXL, CXCR1, DRD1, DRD2, DRD4, EGFR, EPHB4, ERBB2, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, OPRD1, PDGFRB, TEK, TSHR |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.418E-08 | 4.183E-06 | ABL1, EGFR, IGF1R, INSR, KDR, PTK2, SRC |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.751E-07 | 1.234E-05 | ADRA2A, ADRA2B, ADRA2C, AKT1, INSR, SRC |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.847E-07 | 1.285E-05 | ADRA1A, ADRA2A, ADRA2C, AHR, AURKA, AXL, BRAF, DRD2, EGFR, ERBB2, HIF1A, NFKB1, P4HB, PIK3R1, SMAD3, TP53, TYR |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.550E-07 | 1.719E-05 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.445E-07 | 2.234E-05 | ABL1, AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 3.626E-07 | 2.322E-05 | EGFR, ERBB2, INSR, KDR |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 4.058E-07 | 2.565E-05 | ADRA2A, ADRA2B, ADRA2C |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.643E-07 | 2.897E-05 | ABL1, CA2, CA7, DRD1, DRD2, KDR, NPSR1, PDE4D, PLA2G1B, SRC, TRPA1 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 4.705E-07 | 2.927E-05 | ABCC1, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, ALK, AXL, BACE1, DRD1, DRD2, DRD4, EPHB4, FLT3, FLT4, GPR35, IGF1R, INSR, KDR, MET, NPC1, NPSR1, OPRD1, SLC22A6, SLCO1B1, SLCO1B3, TEK, TRPA1, TSHR |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.264E-06 | 7.322E-05 | ADRA2B, ALK, CDK1, DRD4, INSR, MAPK1, PKN1, PLA2G1B, PTPN1 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.279E-06 | 7.386E-05 | ADRB3, HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 1.340E-06 | 7.700E-05 | ABL1, APEX1, AURKA, CDK1, CYP1A1, DUSP3, INSR, PDGFRB, USP2 |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.614E-06 | 9.083E-05 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.614E-06 | 9.083E-05 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.694E-06 | 9.479E-05 | ADRA2A, ADRA2B, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.877E-06 | 1.040E-04 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.888E-06 | 1.043E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, ADRB3, AKT1, AOX1, BLM, CAMK2B, DRD2, FLT3, FLT4, HPGD, MAPT, NFKB1, PYGL, SLC22A6, SMAD3, TYR, XDH |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 2.208E-06 | 1.199E-04 | AXL, IGF1R, INSR, PDGFRB, PIK3R1 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 2.515E-06 | 1.349E-04 | ABL1, AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AOX1, AR, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDK1, CSNK2A1, DUSP3, EPHB4, ERBB2, FLT3, GFER, GLO1, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HSPA1A, LMNA, MAP3K8, MAPK1, MAPT, NEK2, NEK6, NFKB1, PDE4D, PIK3R1, PIM1, PKN1, PLA2G1B, PLK1, PLK4, PTK2, PTPN1, PYGL, RAB9A, SMAD3, SRC, STAT6, TP53, TYR, XDH, XPO1 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 2.634E-06 | 1.399E-04 | FLT3, PDGFRB, PTK2, SRC, TEK |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 3.122E-06 | 1.626E-04 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.122E-06 | 1.626E-04 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 3.454E-06 | 1.765E-04 | ABL1, ADRA2B, ADRA2C, AKT1, ALOX12, AR, AXL, BRAF, CA2, CAMK2B, CDK1, CTDSP1, CYP1B1, DRD2, EGFR, ERBB2, ESR1, ESRRA, GSK3B, HIF1A, INSR, KDR, MAPT, PDGFRB, PIK3R1, PIM1, PTK2, SMAD3, SRC, STAT6, TEK, THPO, XDH |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.677E-06 | 1.871E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 3.794E-06 | 1.921E-04 | FLT3, FLT4, KDR, PDGFRB |
BP | GO:0009987; cellular process | GO:0007200; phospholipase C-activating G-protein coupled receptor signaling pathway | 3.927E-06 | 1.984E-04 | ADRA1A, ADRA2A, DRD1, DRD2, ESR1, NMUR2, OPRD1 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.014E-06 | 1.998E-04 | CYP1A1, CYP2C8, CYP3A4 |
MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 4.014E-06 | 1.998E-04 | ADRA2A, ADRB3, DRD4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.029E-06 | 2.435E-04 | ALOX12, ALOX15, ALOX5, HPGD |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 5.927E-06 | 2.818E-04 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
MF | Unclassified; | GO:0032403; protein complex binding | 7.298E-06 | 3.388E-04 | ABL1, ACHE, ADRA2A, APEX1, EGFR, ESRRB, FLT3, IGF1R, INSR, KDR, MMP13, MMP9, P4HB, PIK3R1, PLK1, PTPN1, SMAD3, SRC, TSHR |
BP | GO:0009987; cellular process | GO:0035791; platelet-derived growth factor receptor-beta signaling pathway | 7.983E-06 | 3.652E-04 | ABL1, PDGFRB, PTPN1 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.983E-06 | 3.652E-04 | CYP1A1, CYP2C8, CYP3A4 |
MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 8.357E-06 | 3.791E-04 | ADRA2A, ADRA2C, ADRB3, PDE4D |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.285E-05 | 5.519E-04 | AKT1, HIF1A, LMNA, OPRD1, P4HB, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.297E-05 | 5.547E-04 | AKT1, EGFR, HBB, INSR, SMAD3 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.389E-05 | 5.863E-04 | FLT3, FLT4, KDR |
MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 1.389E-05 | 5.863E-04 | AKT1, EGFR, ESR1 |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 1.389E-05 | 5.863E-04 | ABCB1, ABCC1, ABCG2 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.606E-05 | 6.648E-04 | CYP1A1, PDGFRB, POLB, TP53 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.612E-05 | 6.648E-04 | AXL, FLT4, KDR, PIK3R1, PTK2, SRC |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.645E-05 | 6.724E-04 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.746E-05 | 7.065E-04 | MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 2.211E-05 | 8.769E-04 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 2.349E-05 | 9.234E-04 | DRD2, DRD4, NMUR2, PLA2G1B |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 2.373E-05 | 9.242E-04 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3, TP53 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 2.940E-05 | 1.127E-03 | ABL1, AKT1, APEX1, BRAF, CA5A, CA5B, CASP1, CDK1, CYP1A1, CYP1B1, CYP2D6, ESR2, GFER, GSK3B, HSD17B10, HSPA1A, MAOA, MAPK1, MMP2, MPO, NFKB1, NOX4, SRC, TP53 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 3.040E-05 | 1.157E-03 | ABCG2, ADRA2A, ADRB3, AHR, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3, TSHR |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 3.298E-05 | 1.243E-03 | BLM, RECQL, TP53 |
BP | GO:0009987; cellular process | GO:0090068; positive regulation of cell cycle process | 4.051E-05 | 1.487E-03 | APEX1, AURKA, AURKB, CDK1, CYP1A1, DRD2, INSR, PDGFRB, PLK4, TP53 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.058E-05 | 1.487E-03 | ABL1, AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKA, AURKB, BLM, CAMK2B, CASP7, CDK1, CSNK2A1, CTDSP1, DUSP3, ESR1, ESR2, ESRRA, ESRRB, GSK3B, HIF1A, HPGD, HSPA1A, LMNA, MAPK1, NEK2, NEK6, NFKB1, NUAK1, PIM1, PKN1, PLK1, POLB, RECQL, SMAD3, SRC, STAT6, THRB, TP53, USP2, XPO1 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.453E-05 | 1.618E-03 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 4.621E-05 | 1.672E-03 | AURKA, AURKB, CDK1, PLK1, POLB |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 4.686E-05 | 1.682E-03 | ABCB1, CA2, CA7 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 4.686E-05 | 1.682E-03 | ABCB1, ABCC1, ABCG2 |
BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 5.277E-05 | 1.862E-03 | DRD1, DRD2, DRD4, MAOA |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 5.277E-05 | 1.862E-03 | AKT1, MAPT, PTPN1, TP53 |
BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 5.519E-05 | 1.913E-03 | AOX1, XDH |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 5.519E-05 | 1.913E-03 | EGFR, NMUR2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.519E-05 | 1.913E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.519E-05 | 1.913E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 5.536E-05 | 1.913E-03 | CDK1, EGFR, IGF1R, INSR, PLA2G1B |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.519E-05 | 1.913E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.519E-05 | 1.913E-03 | ALOX12, ALOX15 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 6.408E-05 | 2.184E-03 | AR, CYP19A1, ESR1 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 6.408E-05 | 2.184E-03 | IGF1R, INSR, PIK3R1 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 7.793E-05 | 2.599E-03 | AKT1, HIF1A, HSPA1A, MMP9, PTPN1, SRC |
BP | GO:0009987; cellular process | GO:0045744; negative regulation of G-protein coupled receptor protein signaling pathway | 7.970E-05 | 2.638E-03 | ADRA2A, ADRB3, DRD2, MET |
BP | GO:0032501; multicellular organismal process | GO:0003014; renal system process | 8.262E-05 | 2.730E-03 | ADRA1A, AKR1B1, DRD2, HBB, PKN1, SLC22A6 |
BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 8.498E-05 | 2.782E-03 | ESR1, MAPK1, STAT6 |
BP | GO:0007610; behavior | GO:0007625; grooming behavior | 8.498E-05 | 2.782E-03 | DRD1, DRD2, NMUR2 |
BP | GO:0008152; metabolic process | GO:0035404; histone-serine phosphorylation | 8.498E-05 | 2.782E-03 | AURKA, AURKB, DRD1 |
BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 8.868E-05 | 2.869E-03 | AKT1, ALK, AR, ESR1, ESR2, HSPA1A, NFKB1, OPRD1, PLA2G1B |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 9.056E-05 | 2.922E-03 | EPHB4, GAA, INSR, PTK2 |
BP | GO:0065007; biological regulation | GO:0010863; positive regulation of phospholipase C activity | 1.025E-04 | 3.276E-03 | ADRA1A, EGFR, ESR1, PDGFRB |
BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.025E-04 | 3.276E-03 | ADRA1A, ADRA2C, AKT1, EGFR |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.099E-04 | 3.467E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.099E-04 | 3.467E-03 | ADRA1A, CA2, CA7 |
MF | GO:0005488; binding | GO:0035240; dopamine binding | 1.099E-04 | 3.467E-03 | DRD1, DRD2, DRD4 |
BP | GO:0008152; metabolic process | GO:1903580; positive regulation of ATP metabolic process | 1.155E-04 | 3.617E-03 | CDK1, ESRRB, HIF1A, INSR |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.221E-04 | 3.815E-03 | AKT1, AR, DAPK1, HSPA1A, LMNA, SRC |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.238E-04 | 3.857E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 1.284E-04 | 3.989E-03 | ADRA1A, ADRA2B, ADRB3, AR, DRD2, HBB, SMAD3 |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 1.332E-04 | 4.113E-03 | FLT3, KDR, PDGFRB, PTK2, TEK |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 1.332E-04 | 4.113E-03 | EGFR, ERBB2, MET, PDGFRB, PIK3R1 |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 1.391E-04 | 4.259E-03 | CYP19A1, ESR1, SRC |
BP | GO:0050896; response to stimulus | GO:1903351; cellular response to dopamine | 1.391E-04 | 4.259E-03 | ABL1, DRD1, MAPK1 |
BP | GO:0008152; metabolic process | GO:0010605; negative regulation of macromolecule metabolic process | 1.505E-04 | 4.585E-03 | ABL1, AHR, AKT1, APEX1, AR, AURKB, BLM, CDK1, CSNK2A1, CTDSP1, DAPK1, DUSP3, EGFR, ESR1, ESR2, ESRRA, GSK3B, HIF1A, HSPA1A, IGF1R, KDR, MAPT, MMP9, NFKB1, OPRD1, PDE4D, PKN1, PLK1, PTPN1, SMAD3, SRC, STAT6, THRB, TP53, USP2, XDH, XPO1 |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.542E-04 | 4.683E-03 | AKR1B1, AKT1, EGFR, HSD17B2, KDR, MMP2, PDGFRB, SLC22A6, SRC, TP53 |
BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 1.616E-04 | 4.822E-03 | AKT1, CA2, PDGFRB, SRC |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.648E-04 | 4.822E-03 | CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 1.648E-04 | 4.822E-03 | GAA, MGAM |
BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 1.648E-04 | 4.822E-03 | ABL1, HIF1A |
BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 1.648E-04 | 4.822E-03 | ABCB1, ABCC1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.648E-04 | 4.822E-03 | CA2, CA7 |
BP | GO:0023052; signaling | GO:0051586; positive regulation of dopamine uptake involved in synaptic transmission | 1.648E-04 | 4.822E-03 | DRD2, DRD4 |
BP | GO:0065007; biological regulation | GO:0051882; mitochondrial depolarization | 1.648E-04 | 4.822E-03 | ABL1, CASP1 |
MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 1.616E-04 | 4.822E-03 | AHR, ESR1, NEK6, TP53 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.648E-04 | 4.822E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.648E-04 | 4.822E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 1.648E-04 | 4.822E-03 | GAA, MGAM |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.648E-04 | 4.822E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.761E-04 | 5.106E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
CC | GO:0043226; organelle | GO:0044454; nuclear chromosome part | 1.782E-04 | 5.160E-03 | APEX1, AR, AURKA, AURKB, BLM, CDK1, CSNK2A1, ESR1, PLK1, SMAD3, STAT6, THRB, TP53 |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 1.796E-04 | 5.179E-03 | AKT1, CASP1, CASP7, PTK2 |
BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 1.875E-04 | 5.380E-03 | ABL1, AKT1, AXL, BRAF, CA2, HIF1A, HSPA1A, MAP3K8, MAPK1, MMP2, NFKB1, PDE4D, PIK3R1, PLA2G1B, PTK2, SRC, STAT6, THPO, TP53 |
CC | GO:0016020; membrane | GO:0005901; caveola | 1.883E-04 | 5.388E-03 | ADRA1A, INSR, MAPK1, SLC22A6, SRC |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.920E-04 | 5.471E-03 | ADRA2A, AKT1, HIF1A, INSR, NOX4, PIK3R1, PYGL |
BP | GO:0009987; cellular process | GO:0038128; ERBB2 signaling pathway | 1.989E-04 | 5.640E-03 | EGFR, ERBB2, PIK3R1, SRC |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.995E-04 | 5.650E-03 | AR, CDK1, ESR1, ESR2, ESRRA, ESRRB, THRB |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 2.091E-04 | 5.883E-03 | ADRA1A, ADRA2C, ADRB3, ALOX12, AXL, CTDSP1, DRD2, EGFR, ERBB2, GPR35, GSK3B, HIF1A, LMNA, NFKB1, PDE4D, PIK3R1, PTK2, SMAD3, TEK, XDH |
BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 2.147E-04 | 5.985E-03 | CA2, ESR1, MAPK1, PDGFRB, TEK |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 2.153E-04 | 5.988E-03 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0002376; immune system process | GO:0050776; regulation of immune response | 2.289E-04 | 6.286E-03 | ABL1, ALOX15, BRAF, DRD2, DUSP3, ESR1, HSPA1A, MAPK1, MMP2, NFKB1, PDE4D, PIK3R1, PKN1, PLA2G1B, PTK2, PTPN1, SMAD3, SRC, STAT6 |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 2.341E-04 | 6.388E-03 | AHR, AR, ESR1, GSK3B, SMAD3, TP53 |
BP | GO:0008152; metabolic process | GO:0051172; negative regulation of nitrogen compound metabolic process | 2.344E-04 | 6.389E-03 | ABL1, ADRA2A, AHR, AKT1, APEX1, AR, AURKB, BLM, CDK1, CSNK2A1, CTDSP1, DAPK1, DRD2, DRD4, DUSP3, EGFR, ESR1, ESR2, ESRRA, HSPA1A, IGF1R, MMP9, NFKB1, PDE4D, PKN1, PLK1, PTPN1, SMAD3, SRC, STAT6, THRB, TP53, USP2, XDH, XPO1 |
BP | GO:0051179; localization | GO:1901386; negative regulation of voltage-gated calcium channel activity | 2.556E-04 | 6.896E-03 | DRD2, DRD4, GPR35 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.556E-04 | 6.896E-03 | AURKB, MAPK1, NEK2 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.556E-04 | 6.896E-03 | CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 2.661E-04 | 7.100E-03 | AKT1, AURKA, AURKB, MAPK1 |
BP | GO:0050896; response to stimulus | GO:0071222; cellular response to lipopolysaccharide | 2.688E-04 | 7.157E-03 | ABL1, AXL, CASP1, NFKB1, PDE4D, SRC |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 2.707E-04 | 7.197E-03 | AR, CA2, CA9, EGFR, ESR1, HIF1A, MET, SMAD3, SRC |
BP | GO:0032502; developmental process | GO:0048538; thymus development | 2.917E-04 | 7.680E-03 | ABL1, BRAF, MAPK1, TYR |
BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 2.929E-04 | 7.693E-03 | CAMK2B, GSK3B, HSPA1A, MAPK1, MAPT |
BP | GO:0008152; metabolic process | GO:0045821; positive regulation of glycolytic process | 3.050E-04 | 8.002E-03 | ESRRB, HIF1A, INSR |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 3.108E-04 | 8.134E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 3.190E-04 | 8.299E-03 | ABL1, AKT1, HIF1A, KDR |
BP | GO:0009987; cellular process | GO:0007077; mitotic nuclear envelope disassembly | 3.190E-04 | 8.299E-03 | CDK1, LMNA, NEK6, PLK1 |
BP | GO:0022610; biological adhesion | GO:0022407; regulation of cell-cell adhesion | 3.233E-04 | 8.390E-03 | ABL1, AKT1, ALOX12, ALOX15, BRAF, DUSP3, ERBB2, MAP3K8, PIK3R1, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.279E-04 | 8.430E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.279E-04 | 8.430E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0005497; androgen binding | 3.279E-04 | 8.430E-03 | ALDH1A1, AR |
MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 3.279E-04 | 8.430E-03 | GAA, MGAM |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 3.356E-04 | 8.557E-03 | CYP1A2, EGFR, ESR1, ESRRA, HPGD, PDGFRB |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 3.481E-04 | 8.788E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 3.491E-04 | 8.788E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 3.491E-04 | 8.788E-03 | AKR1B1, AKT1, AR, EGFR, SRC |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 3.484E-04 | 8.788E-03 | ABL1, ACHE, AKR1B1, APEX1, AURKA, CA4, EGFR, ERBB2, HSPA1A, NOX4, NPC1, SRC, TYR, USP2 |
BP | GO:0040007; growth | GO:0045926; negative regulation of growth | 3.559E-04 | 8.939E-03 | ADRB3, ESR2, HIF1A, HSPA1A, MPO, PTK2, SMAD3, TP53 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 3.566E-04 | 8.947E-03 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1, TP53 |
BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 3.696E-04 | 9.198E-03 | CASP1, CASP7, MAPT, SMAD3, XDH |
BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 3.696E-04 | 9.198E-03 | ALPL, CYP1A1, EGFR, TP53, TYR |
MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 3.696E-04 | 9.198E-03 | AR, CSNK2A1, ESR1, GSK3B, SMAD3 |
BP | Unclassified; | GO:0015758; glucose transport | 3.791E-04 | 9.401E-03 | AKT1, BRAF, DRD1, PLA2G1B |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 3.843E-04 | 9.498E-03 | ABL1, ADRA2B, ADRA2C, AKT1, AR, AURKA, AXL, BRAF, CA2, CAMK2B, DRD2, HIF1A, KDR, MAPT, NFKB1, SMAD3, THPO |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 3.878E-04 | 9.562E-03 | ABL1, ACHE, CASP1, DRD2, EGFR, HIF1A, PLA2G1B, SRC |
BP | GO:0007610; behavior | GO:0007611; learning or memory | 3.878E-04 | 9.562E-03 | BRAF, DRD1, DRD2, EGFR, HIF1A, INSR, MAPK1, MAPT |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.242E-24 | 3.589E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.387E-18 | 3.910E-15 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.374E-15 | 4.336E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.374E-14 | 3.520E-12 | ABCB1, ABCC1, ABCG2, ABL1, AKT1, ALK, AURKA, AURKB, AXL, BLM, BRAF, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, EPHB4, ERBB2, FLT3, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MAPK1, MET, NEK2, NEK6, NUAK1, PDGFRB, PIM1, PKN1, PLK1, PLK4, PTK2, PYGL, RECQL, SRC, TEK, TP53 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.193E-14 | 5.252E-12 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.344E-14 | 1.368E-11 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, TBXAS1, XDH |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.297E-23 | 1.518E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.088E-13 | 7.610E-12 | PDGFRB; GSK3B; SMAD3; FLT3; MMP1; DAPK1; MMP2; BRAF; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PTK2; IGF1R; AR; ERBB2; ABL1; AKT1; MAPK1; MET; TP53 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.098E-13 | 7.610E-12 | CAMK2B; SRC; MMP2; BRAF; PIK3R1; HIF1A; ESR1; MMP9; PTK2; EGFR; IGF1R; ERBB2; KDR; AKT1; MAPK1; TP53; MET |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.528E-13 | 1.315E-11 | MMP1; DAPK1; SRC; MMP2; ERBB2; MAPK1; BRAF; MMP9; TP53; EGFR |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.802E-12 | 7.496E-11 | PDGFRB; GSK3B; AR; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; NFKB1; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.214E-11 | 1.114E-09 | CAMK2B; GSK3B; SRC; ERBB2; ABL1; AKT1; MAPK1; BRAF; PIK3R1; EGFR; PTK2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.771E-11 | 1.418E-09 | PDGFRB; FLT3; ERBB2; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.278E-10 | 4.738E-09 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PIK3R1; PTK2; EGFR; IGF1R; ERBB2; KDR; AKT1; MAPK1; MET |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.324E-10 | 3.443E-09 | PTPN1; SMAD3; CSNK2A1; SRC; INSR; ERBB2; MAPK1; MET; EGFR; IGF1R |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.049E-10 | 7.657E-09 | PDGFRB; SRC; INSR; FLT4; BRAF; PIK3R1; EGFR; IGF1R; KDR; AKT1; MAPK1; TEK; DRD2; MET |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.076E-10 | 4.738E-09 | CAMK2B; INSR; ERBB2; AKT1; MAPK1; TEK; PIK3R1; HIF1A; EGFR; NFKB1; IGF1R |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.173E-10 | 1.568E-08 | PDGFRB; CAMK2B; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; IGF1R |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.055E-09 | 1.568E-08 | PDGFRB; PLA2G1B; INSR; FLT4; PIK3R1; EGFR; NFKB1; IGF1R; KDR; ABL1; AKT1; MAPK1; TEK; MET |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.056E-09 | 1.568E-08 | SMAD3; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; NFKB1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.433E-09 | 3.570E-08 | PDGFRB; GSK3B; INSR; FLT4; PIK3R1; PTK2; EGFR; NFKB1; IGF1R; KDR; AKT1; MAPK1; TEK; PKN1; TP53; MET |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.465E-09 | 2.854E-08 | SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; EGFR; ESR2; HSPA1A |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.060E-09 | 2.678E-08 | PDGFRB; AKT1; MAPK1; BRAF; PIK3R1; TP53; MET; EGFR; IGF1R |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.470E-09 | 2.854E-08 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.272E-09 | 7.820E-08 | CYP2C9; CYP2C8; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; BRAF; ALOX12; CYP2C19 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.420E-09 | 3.570E-08 | GSK3B; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.301E-09 | 6.241E-08 | ALK; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.615E-08 | 4.171E-07 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; FUT7; ALDH2; HSD17B1; ALOX5; HSD17B2; AOX1; XDH; MGAM; GAA; TYR; CYP2C9; CYP2C8; AKR1B10; TBXAS1; CYP1A2; ALDH1A1; CYP1A1; ALPL |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 4.338E-08 | 3.609E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; MAPK1; BRAF; PIK3R1; EGFR; IGF1R |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.446E-08 | 1.308E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; TBXAS1; ALOX12; CYP2C19 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.090E-07 | 7.816E-07 | OPRD1; THRB; GPR35; ADRA2C; ADRA2B; ADRA1A; ADRA2A; TSHR; ADRB3; NMUR2; DRD1; DRD2; DRD4 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.819E-08 | 3.855E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.428E-08 | 2.971E-07 | CYP2C9; CYP2C8; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.380E-08 | 4.144E-07 | SMAD3; ABL1; AKT1; MAPK1; BRAF; PIK3R1; TP53; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.433E-07 | 1.489E-06 | PDGFRB; ABCC1; ABCB1; MMP9; EGFR; NFKB1; ERBB2; PIM1; ABL1; CYP1B1; MAPK1; TP53; MET |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.184E-09 | 1.642E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.858E-07 | 1.246E-06 | GSK3B; THRB; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.147E-07 | 1.353E-06 | CAMK2B; GSK3B; ABL1; AKT1; MAPK1; BRAF; PIK3R1; TP53; NFKB1 |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.690E-07 | 2.132E-06 | OPRD1; ADRB3; INSR; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2B; ADRA1A; ADRA2A |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.695E-07 | 1.176E-06 | FLT3; PIM1; AKT1; MAPK1; BRAF; PIK3R1; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.132E-06 | 5.888E-06 | SMAD3; SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 7.361E-07 | 3.926E-06 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.833E-06 | 9.077E-06 | CAMK2B; PDE4D; AKT1; MAPK1; BRAF; PIK3R1; DRD1; DRD2; NFKB1; TSHR |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.451E-06 | 1.159E-05 | PDGFRB; DUSP3; AKT1; MAPK1; BRAF; MAP3K8; MAPT; TP53; EGFR; NFKB1; HSPA1A |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.311E-06 | 6.651E-06 | CASP7; MMP3; AKT1; MAPK1; MAP3K8; PIK3R1; MMP9; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.061E-07 | 1.819E-06 | GSK3B; SMAD3; AKT1; MAPK1; BRAF; PIK3R1; TP53 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.917E-07 | 1.246E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 6.436E-06 | 2.789E-05 | GSK3B; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1; HSPA1A |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.456E-06 | 2.415E-05 | GSK3B; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.255E-07 | 2.329E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 6.940E-06 | 2.946E-05 | PLK1; CDK1; AKT1; MAPK1; BRAF; PIK3R1; IGF1R |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.474E-06 | 3.390E-05 | SMAD3; MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 8.660E-06 | 3.398E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; BRAF; PIK3R1; NFKB1; PTK2 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 7.560E-06 | 3.145E-05 | PTPN1; GSK3B; INSR; AKT1; MAPK1; BRAF; PIK3R1; PYGL |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.381E-06 | 1.563E-05 | PDGFRB; SRC; CDK1; MAPK1; DRD1; DRD2; EGFR |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.607E-05 | 5.863E-05 | GSK3B; XPO1; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1; HSPA1A |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.099E-06 | 1.015E-05 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.400E-05 | 5.293E-05 | PTPN1; GSK3B; INSR; AKT1; PIK3R1; PYGL; NFKB1 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 4.009E-05 | 1.390E-04 | GSK3B; XPO1; CASP1; AKT1; MAPK1; PIK3R1; NFKB1; HSPA1A |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 3.068E-05 | 1.082E-04 | CAMK2B; AR; PLK1; CDK1; MAPK1; AURKA; IGF1R |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.030E-06 | 2.274E-05 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.616E-05 | 9.383E-05 | OPRD1; ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.010E-05 | 2.243E-04 | CASP7; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 4.166E-05 | 1.420E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD1; DRD2; DRD4 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 8.372E-05 | 2.561E-04 | PDGFRB; CXCR1; INSR; AKT1; MAPK1; PIK3R1; EGFR |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.109E-04 | 3.159E-04 | SMAD3; ADRB3; CXCR1; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 7.666E-05 | 2.380E-04 | GSK3B; SMAD3; ESRRB; AKT1; MAPK1; PIK3R1; IGF1R |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.077E-04 | 3.111E-04 | PDGFRB; POLB; GSK3B; XPO1; SMAD3; AKT1; PIK3R1; TP53; NFKB1 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 7.991E-06 | 3.259E-05 | AKT1; MAPK1; BRAF; PIK3R1; MET; HIF1A |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.072E-05 | 1.985E-04 | INSR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 9.069E-05 | 2.734E-04 | PDGFRB; AKT1; MAPK1; PIK3R1; HIF1A; EGFR |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 3.320E-04 | 8.740E-04 | PDGFRB; CAMK2B; ADRB3; ERBB2; DRD1; ADRA1A; EGFR |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.223E-05 | 4.711E-05 | SLCO1B1; ABCB1; CA2; SLCO1B3; CYP3A4; ABCG2 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.437E-05 | 5.336E-05 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.067E-04 | 3.111E-04 | GSK3B; AKT1; MAPK1; MAP3K8; PIK3R1; NFKB1 |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 6.822E-04 | 1.669E-03 | PDGFRB; CXCR1; THPO; FLT3; FLT4; KDR; MET; EGFR |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.937E-07 | 2.213E-06 | ALDH2; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.134E-04 | 5.840E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; HSPA1A |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.215E-04 | 1.725E-03 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.791E-04 | 7.541E-04 | GSK3B; SMAD3; PLK1; ABL1; CDK1; TP53 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.175E-04 | 8.467E-04 | GSK3B; ABL1; MAPK1; MET; PTK2; EPHB4 |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 9.281E-04 | 2.166E-03 | PDGFRB; SRC; MAPK1; BRAF; PIK3R1; PTK2; EGFR |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 7.945E-04 | 1.878E-03 | GSK3B; CASP7; INSR; AKT1; PIK3R1; NFKB1 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.005E-03 | 2.298E-03 | THPO; PIM1; AKT1; AOX1; STAT6; PIK3R1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 7.163E-04 | 1.725E-03 | CAMK2B; TRPA1; SRC; ALOX12; PIK3R1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.378E-03 | 2.986E-03 | BACE1; GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 5.106E-04 | 1.280E-03 | CAMK2B; SRC; MMP2; MAPK1; EGFR |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.906E-03 | 4.086E-03 | SRC; TBXAS1; AKT1; MAPK1; PIK3R1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.021E-03 | 2.308E-03 | AKT1; MAPK1; MAP3K8; PIK3R1; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 9.372E-04 | 2.166E-03 | SMAD3; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.255E-03 | 2.747E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.829E-04 | 5.073E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.675E-03 | 7.280E-03 | CAMK2B; GSK3B; SMAD3; CSNK2A1; TP53 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.131E-05 | 1.721E-04 | ADRB3; INSR; AKT1; PIK3R1; TSHR |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 4.380E-03 | 8.437E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; ADRA1A |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.046E-03 | 4.299E-03 | INSR; AKT1; PIK3R1; ADRA1A; IGF1R |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.935E-04 | 1.023E-03 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 5.764E-03 | 1.080E-02 | CAMK2B; SRC; MAPK1; PIK3R1; EGFR |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 9.405E-03 | 1.672E-02 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 9.621E-03 | 1.696E-02 | MAOA; MAPK1; BRAF; DRD1; DRD2 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.168E-05 | 2.259E-04 | AKT1; MAPK1; BRAF; PIK3R1; HIF1A |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 9.779E-05 | 2.906E-04 | INSR; AKT1; PIK3R1; HSPA1A; IGF1R |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.532E-02 | 2.509E-02 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.050E-02 | 1.836E-02 | MMP2; PIK3R1; MMP9; PTK2 |
hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 1.112E-02 | 1.928E-02 | PLA2G1B; MAPK1; BRAF; ADRA1A |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 5.926E-03 | 1.100E-02 | CAMK2B; GSK3B; MAPK1; TYR |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.964E-02 | 4.636E-02 | AKT1; MAPK1; PIK3R1 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.307E-04 | 3.672E-04 | CXCR1; SRC; MET; EGFR; NFKB1 |
hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 2.725E-02 | 4.294E-02 | MMP1; MMP3; TEK |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 3.467E-03 | 6.933E-03 | CASP1; MAPK1; PKN1; NFKB1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.434E-03 | 4.963E-03 | SRC; PIK3R1; MET; PTK2 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.109E-03 | 4.386E-03 | CASP7; CASP1; MAPK1; NFKB1 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.303E-02 | 2.150E-02 | AKT1; MAPK1; PIK3R1 |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 1.202E-02 | 2.032E-02 | CAMK2B; MAPK1; BRAF |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.241E-03 | 2.747E-03 | SRC; ABL1; MAPK1; NFKB1 |
hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 1.252E-02 | 2.100E-02 | CAMK2B; MAOA; DRD1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.611E-04 | 1.637E-03 | CASP7; CASP1; NFKB1; HSPA1A |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 9.272E-03 | 1.663E-02 | MAPK1; BRAF; IGF1R |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.153E-02 | 1.982E-02 | SMAD3; STAT6; NFKB1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 8.053E-03 | 1.469E-02 | CASP1; MAPK1; NFKB1 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 8.854E-03 | 1.601E-02 | AKR1B10; ALDH2; AKR1B1 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.246E-04 | 1.090E-03 | MAOA; DRD1; DRD2; NFKB1 |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 7.669E-03 | 1.412E-02 | MGAM; GAA; PYGL |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 4.989E-03 | 9.434E-03 | INSR; MAPK1; PIK3R1 |
hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 4.989E-03 | 9.434E-03 | ALDH2; AOX1; HSD17B10 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 4.158E-03 | 8.082E-03 | MGAM; AKT1; PIK3R1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 6.106E-05 | 1.985E-04 | MGAM; AKR1B10; GAA; AKR1B1 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.901E-03 | 7.655E-03 | ABCC1; ABCB1; ABCG2 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.763E-03 | 5.580E-03 | INSR; MAPK1; PIK3R1 |
hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 2.623E-02 | 4.165E-02 | MAPK1; HSPA1A |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.349E-02 | 3.759E-02 | POLB; APEX1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.217E-02 | 3.575E-02 | AKR1B10; AKR1B1 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.606E-02 | 2.610E-02 | MAPK1; EGFR |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.164E-03 | 2.604E-03 | MAPK1; BRAF; TP53 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.021E-03 | 4.289E-03 | MAOA; AOX1; TYR |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.193E-03 | 4.516E-03 | AKR1B10; ALDH2; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.180E-02 | 2.011E-02 | CA2; CA4 |
hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 1.281E-02 | 2.131E-02 | ALDH2; MAOA |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.076E-04 | 1.280E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR; ERBB2 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA1A; ADRA2C; ADRB3; DRD2 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; DRD2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
NA: NA | Inflammatory diseases | NA | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ABCB1; IGF1R; IGF1R; PDGFRB; EGFR; EGFR; AXL; DRD2; KDR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; ESRRA |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
NA: NA | GIST | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
NA: NA | Itching | NA | DRD2 |
A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | ADRB3 |
C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK |
I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; ADRA2B |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1A; ADRA2C; ADRB3; DRD1; DRD2; DRD2 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; ESR1 |
I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | PDE4D; PDE4D; PDE4D; MPO; ALOX5; ADRB3; DRD2 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1 |
A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
NA: NA | Hyperaemia | NA | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; ADRB3; ADRB3; ADRB3 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
NA: NA | HIV infections | NA | AHR |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
NA: NA | Corneal vascularity | NA | DRD2 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; INSR; MMP13; OPRD1; ACHE; IGF1R; ADRA1A; CDK1; ADRA2C; ADRA2A; TRPA1; ESR1; DRD1; DRD2 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; BRAF; DRD1; DRD2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; TEK; ALOX5; MMP1 |
NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; FLT4; KDR |
C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; EGFR; EGFR; ERBB2; TP53; KDR |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; ADRB3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; CYP2C9; DRD2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PDE4D; PDE4D; TBXAS1; PLA2G1B; ESRRA; ALOX5; ALOX5; ERBB2; ADRA2C; ADRB3; ADRB3; DRD2 |
J00-J99: Diseases of the respiratory system | Emphysema | J43 | PDE4D |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; ADRA1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; ESR1 |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; ADRB3 |
I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM; GAA |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
C00-D49: Neoplasms | Breast cancer | C50 | AR; INSR; FLT3; FLT3; CA9; IGF1R; CYP19A1; CDK1; EGFR; EGFR; EGFR; ERBB2; ERBB2; ERBB2; ESR1; ESR1; DRD2; KDR; KDR; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2; EGFR; DRD2 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; EGFR; KDR; PLK1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
NA: NA | False perceptions | NA | DRD2 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADRA1A; DRD1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; OPRD1; ACHE; CYP3A4; DRD2 |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | PDE4D; DRD2 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ADRA1A; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1; DRD2 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; ERBB2; KDR; KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1; MMP2; EGFR; EGFR; KDR; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A |
O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR; ESR1 |
N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2; DRD1; DRD2 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | PDE4D; ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
NA: NA | Peripheral vasoconstriction | NA | DRD2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR; ERBB2 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; BRAF; KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; ALOX5 |
J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; ADRA1A |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ABL1; FLT4; ADRA1A; EGFR; ERBB2; ESR1; PLK1 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1; SRC |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; AURKA; PLK1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; MGAM; KDR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; CSNK2A1; ABCB1; CA1; FLT3; FLT3; CA9; ABL1; MMP2; ACHE; SRC; IGF1R; PTK2; BRAF; BRAF; AURKA; FLT4; EPHB4; TEK; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; EGFR; ERBB2; ERBB2; PIM1; TP53; ESR1; ESR1; XPO1; KDR; PLK1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; CASP1; OPRD1; MMP3; ALOX5; TYR; MMP1 |
H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
NA: NA | Schizoaffective disorders | NA | DRD2 |
NA: NA | Vomiting | NA | DRD2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2; OPRD1; ADRA2C; ADRA2B; DRD2 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB; INSR; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4; DRD1; DRD2; DRD2; DRD2; DRD2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; INSR; MAPT; ACHE; ACHE; ACHE; GSK3B; ADRA2C; DRD2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; DRD2 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; AURKA; TP53; TP53; PLK1 |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM; INSR; PTPN1; PDGFRB; GSK3B; ADRB3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | ADRB3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; ADRA1A; ADRB3 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; OPRD1; ADRA1A; ADRB3; ADRB3; DRD2 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | BRAF; EGFR; TYR; KDR; KDR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
NA: NA | Malignant essential hypertension | NA | DRD2 |
NA: NA | Menopausal disorder | NA | ESR1 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; DRD2 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
C00-D49: Neoplasms | Solid tumors | NA | BRAF |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; MGAM; INSR; PTPN1; PTPN1; NFKB1; ADRB3; ADRB3; ADRB3; DRD1 |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3; EGFR |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1; ADRB3; DRD2 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ABL1; ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; BRAF; AURKA; TP53 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | PDE4D; FLT3; ALOX5; EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; ADRA1A |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; MMP13; ALOX5; DRD2 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; CA9; HIF1A; EGFR; ERBB2; PLK1 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; MMP2; FLT4; EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; ABCB1; FLT3; CA9; ABL1; MMP2; SRC; IGF1R; PTK2; AURKB; AURKA; FLT4; TEK; PDGFRB; HIF1A; MAPK1; MMP9; EGFR; ERBB2; TP53; XPO1; KDR; KDR; KDR; PLK1; PLK1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4; DRD1; DRD2 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |